Revolution Medicines IncRVMD
ASignal's systematic analysis rates RVMD as Neutral.
Reflects the latest available analysis · analyzed Aug 30, 2026
The case on RVMD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $3.94B in total cash
- Low debt-to-equity ratio of 0.46x indicating manageable leverage
- High current and quick ratios (11.38x and 11.12x) signaling strong liquidity
- Positive MACD histogram expansion suggests potential momentum shift
- Negative operating cash flow of $-1.22B
- Negative free cash flow of $-711.61M
- Negative return on equity (-79.09%) and return on assets (-30.12%)
- Negative price momentum and MACD below signal line
- Lack of profitability with zero operating and gross margins
- High valuation metrics including negative forward P/E and EV/EBITDA
See the full verdict on RVMD
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RVMD
Most investors never get a second opinion, let alone several. ASignal runs RVMD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.